Book a Meeting

Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody (CAT#: BioBet-1794ZP) Datasheet

Target
CD19
Isotype
IgG1
Description
Non-Fucosylated Anti-Human CD19 (GBR 401) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 molecule
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Gene ID
930
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
GBR 401
Host
Humanized afucosylated
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

Anti-CD19 Antibody, Non-Fucosylated (CAT#: BioBet-010ZP)
Highly Galactosylated Anti-CD19 (denintuzumab mafodotin) Antibody (CAT#: BioBet-GA-107ZP)
Non-fucosylated Anti-Human CD19 (Denintuzumab) Therapeutic Antibody (CAT#: BioBet-105ZP)
Non-Fucosylated Anti-Human CD19 (R005-1) Therapeutic Antibody (CAT#: BioBet-1694ZP)
Non-Fucosylated Anti-Human CD19 (Tafasitamab) Therapeutic Antibody (CAT#: BioBet-1835ZP)
Non-Fucosylated Anti-Human CD19 (3649-aFuc) Therapeutic Antibody (CAT#: BioBet-1674ZP)
Anti-CD19 Antibody, ADCC Enchanced (CAT#: BioBet-CB-003LX)
Highly Galactosylated Anti-CD19 (Taplitumomab paptox) Antibody (CAT#: BioBet-GA-103ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.